NTRK3 and colorectal cancer: Notably, LOXO-195 possessed antitumor activity in two patients that had LMNA-NTRK1 fusion-positive colorectal cancer and ETV6-NTRK3 fusion-positive infantile fibrosarcoma with TRKA G595R- and TRKC G623R-driven acquired resistance to larotrectinib, respectively (88).